Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + TKI + GEMOX in Advanced Biliary Tract Cancers
NCT06320301Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Apr 2024
- Primary completion
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in biliary tract cancer (BTC), sponsored by Sun Yat-sen Memorial Hospital. Started Apr 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06320301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06320301.